AstraZeneca (LON:AZN) Given “Overweight” Rating at JPMorgan Chase & Co.

AstraZeneca (LON:AZN)‘s stock had its “overweight” rating restated by equities researchers at JPMorgan Chase & Co. in a research note issued to investors on Friday, Marketbeat Ratings reports. They currently have a £140 ($175.50) price target on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 33.66% from the company’s previous close.

Other equities analysts have also recently issued reports about the stock. Berenberg Bank reissued a “buy” rating and issued a £150 ($188.04) target price on shares of AstraZeneca in a research note on Monday, September 2nd. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a £110 ($137.90) price target on shares of AstraZeneca in a report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus target price of £104.12 ($130.53).

AstraZeneca Price Performance

LON:AZN opened at £104.74 ($131.30) on Friday. AstraZeneca has a 1-year low of GBX 9,461 ($118.60) and a 1-year high of £133.88 ($167.83). The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. The firm has a fifty day simple moving average of £113.52 and a 200 day simple moving average of £120.66. The stock has a market capitalization of £162.35 billion, a PE ratio of 3,325.08, a P/E/G ratio of 0.86 and a beta of 0.17.

Insider Transactions at AstraZeneca

In other news, insider Pascal Soriot bought 20,000 shares of the company’s stock in a transaction dated Thursday, November 14th. The stock was bought at an average price of £102.03 ($127.91) per share, with a total value of £2,040,600 ($2,558,104.55). Also, insider Tony Mok purchased 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was bought at an average cost of £126.80 ($158.96) per share, with a total value of £190,200 ($238,435.50). Over the last 90 days, insiders bought 23,500 shares of company stock valued at $223,316,000. 0.04% of the stock is currently owned by corporate insiders.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.